company background image
1D5A logo

PLx Pharma Winddown DB:1D5A Stock Report

Last Price

€0.0005

Market Cap

€5.4k

7D

0%

1Y

-99.9%

Updated

19 Aug, 2023

Data

Company Financials

1D5A Stock Overview

PLx Pharma Winddown Corp. operates as a commercial-stage drug delivery platform technology company in the United States.

1D5A fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health4/6
Dividends0/6

PLx Pharma Winddown Corp. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for PLx Pharma Winddown
Historical stock prices
Current Share PriceUS$0.0005
52 Week HighUS$0.97
52 Week LowUS$0.0005
Beta3.41
1 Month Change0%
3 Month Change0%
1 Year Change-99.94%
3 Year Change-99.98%
5 Year Change-99.98%
Change since IPO-99.99%

Recent News & Updates

Recent updates

Shareholder Returns

1D5ADE PharmaceuticalsDE Market
7D0%-2.6%-0.4%
1Y-99.9%-27.1%5.0%

Return vs Industry: 1D5A underperformed the German Pharmaceuticals industry which returned -28.2% over the past year.

Return vs Market: 1D5A underperformed the German Market which returned 5.9% over the past year.

Price Volatility

Is 1D5A's price volatile compared to industry and market?
1D5A volatility
1D5A Average Weekly Movementn/a
Pharmaceuticals Industry Average Movement6.1%
Market Average Movement4.8%
10% most volatile stocks in DE Market10.3%
10% least volatile stocks in DE Market2.5%

Stable Share Price: 1D5A has not had significant price volatility in the past 3 months.

Volatility Over Time: Insufficient data to determine 1D5A's volatility change over the past year.

About the Company

FoundedEmployeesCEOWebsite
200218Pat Lonerganhttps://plxpharma.com

PLx Pharma Winddown Corp. operates as a commercial-stage drug delivery platform technology company in the United States. The company’s lead product candidates are Vazalore 325 mg for the patients with vascular events, such as heart attacks and clot-related strokes, as well as for use in conditions associated with pain and inflammation, including other aspirin and non-steroidal anti-inflammatory drug products; and Vazalore 81 mg liquid-filled aspirin capsules. Its product pipeline also includes PL1200 Ibuprofen 200 mg; and PL1100 Ibuprofen 400 mg, which are in Phase I clinical stage for pain, inflammation, and fever.

PLx Pharma Winddown Corp. Fundamentals Summary

How do PLx Pharma Winddown's earnings and revenue compare to its market cap?
1D5A fundamental statistics
Market cap€5.36k
Earnings (TTM)-€25.36m
Revenue (TTM)€4.18m

0.0x

P/S Ratio

0.0x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
1D5A income statement (TTM)
RevenueUS$4.54m
Cost of RevenueUS$4.34m
Gross ProfitUS$203.00k
Other ExpensesUS$27.78m
Earnings-US$27.58m

Last Reported Earnings

Sep 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-0.95
Gross Margin4.47%
Net Profit Margin-606.91%
Debt/Equity Ratio0%

How did 1D5A perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.